Drug Profile
Research programme: cancer immunotherapies - Genocea Biosciences
Alternative Names: Neoantigen cancer vaccines - Genocea BiosciencesLatest Information Update: 27 Mar 2023
Price :
$50
*
At a glance
- Originator Genocea Biosciences; Memorial Sloan-Kettering Cancer Center
- Developer Dana-Farber Cancer Institute; Genocea Biosciences; Harvard Medical School; Memorial Sloan-Kettering Cancer Center; US Oncology Research
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer; Malignant melanoma